Short answer
Strata Critical Medical, Inc. (SRTA) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 fiscal 2026 results announced for quarter ended September 30, 2026.
Strata Critical Medical, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 fiscal 2026 results announced for quarter ended September 30, 2026
- Press release Exhibit 99.1 contains the financial results and investor-relevant performance details
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $74.1M, up 50.3% year over year, driven by acquisitions and clinical revenue growth
- Clinical revenue $29.2M, up 20.3% sequentially, while Logistics revenue declined 3.5% to $44.9M
- Adjusted EBITDA $9.6M, margin 13.0%, up 450 basis points year over year
- Operating cash flow $9.5M and free cash flow $8.6M, supporting continued acquisitions and shareholder returns
- $20M share repurchase authorization alongside M&A, with $41.6M cash and short-term investments at quarter-end
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Strata Critical Medical, Inc. 8-K filings
Get the next SRTA 8-K as it lands
Follow SRTA for push alerts, or ask the research agent what this filing means.